Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.00420-05PMID 17065621PMCID PMC1635234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic-Pharmacodynamic Relationship of Arbekacin for Treatment of Patients Infected with Methicillin-Resistant Staphylococcus aureus

  2006cited by this paper
• Gentamicin volume of distribution in critically ill septic patients

  2005cited by this paper
• The effect of sepsis upon gentamicin pharmacokinetics in neonates.

  2005cited by this paper
• Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates

  2004cited by this paper
• The Use of a Change in Gentamicin Clearance as an Early Predictor of Gentamicin‐Induced Nephrotoxicity

  2003cited by this paper
• Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants

  2003cited by this paper
• Population pharmacokinetics of gentamicin in patients with cancer.

  2002cited by this paper
• A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

  1999influential reference
• Population pharmacokinetics of amikacin in patients with haematological malignancies.

  1999cited by this paper
• Factors affecting gentamicin pharmacokinetics in septic patients

  1999cited by this paper
• Clinical pharmacokinetics of ciprofloxacin in patients with major burns

  1999cited by this paper
• Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria

  1999cited by this paper
• Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity

  1999cited by this paper
• Population pharmacokinetics of vancomycin in Japanese adult patients.

  1998cited by this paper
• Decreased Susceptibilities to Teicoplanin and Vancomycin among Coagulase-Negative Methicillin-Resistant Clinical Isolates of Staphylococci

  1998cited by this paper
• A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.

  1998cited by this paper
• Tobramycin population pharmacokinetics in neonates *

  1997cited by this paper
• Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality

  1997cited by this paper
• Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus.

  1997cited by this paper
• Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

  1997cited by this paper
• Stability and Performance of a Population Pharmacokinetic Model

  1997cited by this paper
• Ciprofloxacin pharmacokinetics in burn patients

  1996cited by this paper
• Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus.

  1995cited by this paper
• Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

  1995cited by this paper
• [Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man].

  1994cited by this paper
• Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin.

  1994cited by this paper
• Aminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients

  1993cited by this paper
• Aminoglycoside volume of distribution in postoperative patients with septic shock.

  1993cited by this paper
• Altered aminoglycoside volume of distribution in patients with acquired immunodeficiency syndrome.

  1991cited by this paper
• [Clinical study of aminoglycosides on renal dysfunction--pharmacokinetics of arbekacin and its elimination effects by hemodialysis and adsorption with charcoal].

  1989cited by this paper
• [Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency].

  1989cited by this paper
• [The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus].

  1988cited by this paper
• [Absorption, distribution, and excretion of arbekacin after intravenous and intramuscular administration in rats].

  1987cited by this paper
• Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

  1987cited by this paper
• Pharmacokinetics of habekacin in patients with renal insufficiency

  1987cited by this paper
• An overview of amikacin.

  1985cited by this paper
• Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

  1984cited by this paper
• Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations

  1982cited by this paper
• Prospective Comparative Study of Variable Dosage and Variable Frequency Regimens for Administration of Gentamicin

  1975cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria.

  1973cited by this paper

• Body Mass Index of Elderly Patients with Normal Renal Function as a Determining Factor for Initial Vancomycin Regimen Designing

  2022cites this paper
• Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study.

  2020cites this paper
• Increased arbekacin clearance in patients with febrile neutropenia.

  2020cites this paper
• Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution

  2019cites this paper
• The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients

  2019cites this paper
• Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem‐Cell Transplantation

  2018cites this paper
• Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens.

  2016cites this paper
• Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

  2014cites this paper
• Comparative Pharmacokinetics of Kanamycin between Multi-drug Resistant Tuberculosis Patients and Healthy Volunteers

  2014cites this paper
• Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

  2014cites this paper
• New Methodology to Estimate Pediatric Doses Based on Drug Elimination Processes and Physiological and Biochemical Developmental Factors

  2014cites this paper
• Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers.

  2014cites this paper
• Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

  2013cites this paper
• Rapid quantification of the aminoglycoside arbekacin in serum using high performance liquid chromatography-tandem mass spectrometry.

  2013influential citation
• Population pharmacokinetics of tazobactam/piperacillin in Japanese patients with community-acquired pneumonia.

  2013cites this paper
• [Optimization of antimicrobial therapy based on therapeutic drug monitoring].

  2012cites this paper
• Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients

  2012cites this paper
• The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection

  2012cites this paper
• Evaluation of arbekacin anti-MRSA agents for adult in Japan.

  2012cites this paper
• Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA.

  2011cites this paper
• Therapeutic Drug Monitoring (TDM）に基づく抗菌薬の適正使用

  2011cites this paper
• Aminoglycosides and aminocyclitols

  2011cites this paper
• Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation

  2011cites this paper
• Comparative pharmacokinetics/pharmacodynamic modeling on three brands of 10% enrofloxacin oral formulations in broiler chickens.

  2010cites this paper
• Factors Influencing Peak Concentrations of Arbekacin in Patients

  2009cites this paper
• Population pharmacokinetic analysis of vancomycin in patients with gram‐positive infections and the influence of infectious disease type

  2009cites this paper
• [Dose estimation for renal-excretion drugs in neonates and infants based on physiological development of renal function].

  2009cites this paper
• Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia.

  2008cites this paper
• ABK1日1回投与法 (once a day投与) の承認に寄せて

  2008cites this paper
• Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose‐setting of arbekacin

  2008cites this paper
• Recommended dose of arbekacin, an aminoglycoside against methicillin‐resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance

  2008cites this paper
• Population pharmacokinetics of arbekacin in burn patients

  2008influential citation
• Influences of dosage regimen and co-administration of low-molecular weight proteins and basic peptides on renal accumulation of arbekacin in mice.

  2008cites this paper
• Staphylococci.

  2007cites this paper
• Regulation of drug transporters during infection and inflammation.

  2007cites this paper
• Pharmacokinetic-Pharmacodynamic Relationship of Arbekacin for Treatment of Patients Infected with Methicillin-Resistant Staphylococcus aureus

  2006influential citation
• Population Pharmacokinetic Analysis of Arbekacin in Pediatric Patients

  2006cites this paper